Attached files
file | filename |
---|---|
EX-16.1 - EX-16.1 - Kite Pharma, Inc. | d803283dex161.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): October 7, 2014
Kite Pharma, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-36508 | 27-1524986 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
2225 Colorado Avenue Santa Monica, California |
90404 | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (310) 824-9999
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 4.01 | Changes in Registrants Certifying Accountant. |
On October 7, 2014, Kite Pharma, Inc. (Kite) notified Crowe Horwath LLP (the Former Accounting Firm) they had been dismissed as its independent registered public accounting firm and engaged Ernst & Young LLP (the New Accounting Firm), as its new independent registered public accounting firm. Kites audit committee approved the change in independent accountants.
The audit reports of the Former Accounting Firm on Kites financial statements as of and for the fiscal years ended December 31, 2013 and 2012 did not contain an adverse opinion or disclaimer of opinion, nor were such reports qualified or modified as to uncertainty, audit scope or accounting principles.
During the two fiscal years ended December 31, 2013 and 2012 and through October 7, 2014, there were no (a) disagreements between Kite and the Former Accounting Firm on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which, if not resolved to the satisfaction of the Former Accounting Firm, would have caused the Former Accounting Firm to make reference thereto in connection with its opinion on the financial statements for such years or (b) reportable events, as such term is defined in Item 304(a)(1)(v) of Regulation S-K.
Kite provided the Former Accounting Firm with a copy of this Current Report on Form 8-K, and requested that the Former Accounting Firm furnish it with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the above statements. A copy of such letter, dated October 14, 2014, is filed as Exhibit 16.1 to this Current Report on Form 8-K.
During Kites two most recent fiscal years and the subsequent interim period prior to the engagement of the New Accounting Firm, Kite did not consult with the New Accounting Firm regarding (a) the application of accounting principles to a specified transaction, either completed or proposed; (b) the type of audit opinion that might be rendered on Kites financial statements, and neither a written report was provided to Kite or oral advice was provided that the New Accounting Firm concluded was an important factor considered by Kite in reaching a decision as to an accounting, auditing or financial reporting issue; or (c) any matter that was the subject of a disagreement or reportable event as defined in Items 304(a)(1)(iv) and (v), respectively, of Regulation S-K with the Former Accounting Firm.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibit is filed as part of this Current Report:
16.1 | Letter from Crowe Horwath LLP, dated October 14, 2014, regarding the change in independent registered public accounting firms |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 14, 2014 | KITE PHARMA, INC. (Registrant) | |||||
By: | /s/ Cynthia M. Butitta | |||||
Name: | Cynthia M. Butitta | |||||
Title: | Chief Operating Officer and Chief Financial Officer |